NovoCure (NASDAQ: NVCR) chair nets large awards, sells shares for taxes
Rhea-AI Filing Summary
NovoCure Ltd Executive Chairman William F. Doyle reported multiple equity compensation transactions on March 3, 2026. He received stock options for 258,445 shares and an additional option grant for 30,072 shares, which are scheduled to vest in equal parts over four years, subject to continued employment.
On the same date, he acquired 200,000 ordinary shares from restricted share units that vest over three years and 200,284 ordinary shares from performance-based restricted stock units that vested. He then sold 50,557 and 21,330 ordinary shares at weighted average prices of $12.7865 and $13.4288 to cover tax withholding obligations under a mandatory “sell to cover” provision, leaving 328,397 ordinary shares held directly.
Positive
- None.
Negative
- None.
Insights
Large equity awards paired with mandatory tax sales, net position increases.
William F. Doyle, Executive Chairman of NovoCure Ltd, received substantial equity compensation on March 3, 2026. Awards include 288,517 stock options and 400,284 ordinary shares from time-based and performance-based restricted stock units, significantly increasing his potential equity exposure.
The filing shows open-market sales totaling 71,887 ordinary shares at weighted average prices of $12.7865 and $13.4288. Footnotes state these sales were mandated “sell to cover” trades to satisfy tax withholding obligations tied to performance-based RSU vesting, rather than discretionary sales.
After these transactions, Doyle directly holds 328,397 ordinary shares. Because the equity grants materially exceed the tax-related share sales, his overall ownership rises, suggesting continued alignment of leadership incentives with shareholder outcomes, based solely on the disclosed share counts and vesting structures.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 258,445 | $0.00 | -- |
| Grant/Award | Stock Option (Right to Buy) | 30,072 | $0.00 | -- |
| Grant/Award | Ordinary Shares | 200,000 | $0.00 | -- |
| Grant/Award | Ordinary Shares | 200,284 | $0.00 | -- |
| Sale | Ordinary Shares | 50,557 | $12.7865 | $646K |
| Sale | Ordinary Shares | 21,330 | $13.4288 | $286K |
Footnotes (1)
- Represents restricted share units that are scheduled to vest in equal parts on the first, second and third anniversary of the grant date, subject to the reporting person's continued employment through such dates. Represents vesting of performance-based restricted stock units. Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Performance-Based Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. This transaction was executed in multiple trades at prices ranging from $12.299 USD to $13.277 USD; the price reported above reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $13.35 USD to $13.52 USD; the price reported above reflects the weighted average sale price. Options to buy ordinary shares that are scheduled to vest in equal parts on the first, second, third and fourth anniversary of the grant date, subject to the reporting person's continued employment through such date.
